Tap, W. D., & Hohenberger, P. (2017). Doxorubicin plus evofosfamide versus doxorubicin alone in locally advanced, unresectable or metastatic soft-tissue sarcoma (TH CR-406/SARC021): An international, multicentre, open-label, randomised phase 3 trial. The lancet. Oncology, 18(8), . https://doi.org/10.1016/S1470-2045(17)30381-9
Chicago-Zitierstil (17. Ausg.)Tap, William D., und Peter Hohenberger. "Doxorubicin Plus Evofosfamide Versus Doxorubicin Alone in Locally Advanced, Unresectable or Metastatic Soft-tissue Sarcoma (TH CR-406/SARC021): An International, Multicentre, Open-label, Randomised Phase 3 Trial." The Lancet. Oncology 18, no. 8 (2017). https://doi.org/10.1016/S1470-2045(17)30381-9.
MLA-Zitierstil (9. Ausg.)Tap, William D., und Peter Hohenberger. "Doxorubicin Plus Evofosfamide Versus Doxorubicin Alone in Locally Advanced, Unresectable or Metastatic Soft-tissue Sarcoma (TH CR-406/SARC021): An International, Multicentre, Open-label, Randomised Phase 3 Trial." The Lancet. Oncology, vol. 18, no. 8, 2017, https://doi.org/10.1016/S1470-2045(17)30381-9.